RATIONALE: There is conflicting evidence regarding sex differences in the outcome from severe sepsis and toxic shock. Superantigen-mediated toxic shock affects a higher proportion of female patients. OBJECTIVES: The objective of the current study was to investigate sexual dimorphism in superantigen-associated sepsis and in superantigen-mediated shock and to identify the key mechanisms responsible for this sex difference. METHODS: We measured mortality and serum cytokines after induction of sepsis with isogenic superantigen-positive and superantigen-negative Streptococcus pyogenes in HLA class II transgenics. During superantigen-mediated toxic shock, we measured mortality, T-cell responses, systemic tumor necrosis factor (TNF)-alpha and TNF receptors, TNF-alpha-induced hepatocyte apoptosis, and conditioning of these responses by tamoxifen treatment. MEASUREMENTS AND MAIN RESULTS: In both superantigen-associated sepsis and in superantigen-mediated shock, serum TNF-alpha was increased in females compared with males. This was not attributable to a detectable difference in splenic TNF-alpha transcription; rather, serum soluble TNF receptors were higher in males. Pretreatment of females with the estrogen receptor modulator tamoxifen increased serum soluble TNF receptors, reduced the early serum TNF-alpha response, and improved mortality in females challenged with staphylococcal enterotoxin B. Lethal superantigen shock was characterized by hepatocyte apoptosis, and was reproduced by injection of TNF-alpha. Females had enhanced susceptibility to TNF-alpha-mediated lethality. TNF-alpha-induced hepatocyte apoptosis was greater in females, and was reduced by tamoxifen pretreatment. CONCLUSIONS: Sexual dimorphism in experimental superantigen toxic shock results from increased systemic TNF-alpha in females, coupled with an increased susceptibility to TNF-alpha-induced hepatocyte apoptosis. Both processes are abrogated by estrogen receptor modulators.
RATIONALE: There is conflicting evidence regarding sex differences in the outcome from severe sepsis and toxic shock. Superantigen-mediated toxic shock affects a higher proportion of female patients. OBJECTIVES: The objective of the current study was to investigate sexual dimorphism in superantigen-associated sepsis and in superantigen-mediated shock and to identify the key mechanisms responsible for this sex difference. METHODS: We measured mortality and serum cytokines after induction of sepsis with isogenic superantigen-positive and superantigen-negative Streptococcus pyogenes in HLA class II transgenics. During superantigen-mediated toxic shock, we measured mortality, T-cell responses, systemic tumor necrosis factor (TNF)-alpha and TNF receptors, TNF-alpha-induced hepatocyte apoptosis, and conditioning of these responses by tamoxifen treatment. MEASUREMENTS AND MAIN RESULTS: In both superantigen-associated sepsis and in superantigen-mediated shock, serum TNF-alpha was increased in females compared with males. This was not attributable to a detectable difference in splenic TNF-alpha transcription; rather, serum soluble TNF receptors were higher in males. Pretreatment of females with the estrogen receptor modulator tamoxifen increased serum soluble TNF receptors, reduced the early serum TNF-alpha response, and improved mortality in females challenged with staphylococcal enterotoxin B. Lethal superantigen shock was characterized by hepatocyte apoptosis, and was reproduced by injection of TNF-alpha. Females had enhanced susceptibility to TNF-alpha-mediated lethality. TNF-alpha-induced hepatocyte apoptosis was greater in females, and was reduced by tamoxifen pretreatment. CONCLUSIONS: Sexual dimorphism in experimental superantigen toxic shock results from increased systemic TNF-alpha in females, coupled with an increased susceptibility to TNF-alpha-induced hepatocyte apoptosis. Both processes are abrogated by estrogen receptor modulators.
Authors: Deborah L W Chong; Rebecca J Ingram; Daniel E Lowther; Roshell Muir; Shiranee Sriskandan; Daniel M Altmann Journal: Immunology Date: 2012-07 Impact factor: 7.397
Authors: Christine M Alvarado; Jose A Diaz; Angela E Hawley; Shirley K Wrobleski; Robert E Sigler; Daniel D Myers Journal: Thromb Res Date: 2011-02-05 Impact factor: 3.944
Authors: Orlando Laitano; Gerard P Robinson; Christian K Garcia; Alex J Mattingly; Laila H Sheikh; Kevin O Murray; John D Iwaniec; Jamal Alzahrani; Deborah Morse; Juan Hidalgo; Thomas L Clanton Journal: Shock Date: 2021-05-01 Impact factor: 3.454
Authors: Majid Asiabanha; Gholamreza Asadikaram; Amir Rahnema; Mehdi Mahmoodi; Gholamhosein Hasanshahi; Mohammad Hashemi; Mohammad Khaksari Journal: Korean J Physiol Pharmacol Date: 2011-12-27 Impact factor: 2.016
Authors: Hema Sharma; Claire E Turner; Matthew K Siggins; Mona El-Bahrawy; Bruno Pichon; Angela Kearns; Shiranee Sriskandan Journal: mSphere Date: 2019-10-09 Impact factor: 4.389